- Home
- AGPU vs NRXS Comparison
AGPU vs NRXS Comparison
Compare AGPU & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | AGPU | NRXS |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 78.9M |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | AGPU | NRXS |
|---|---|---|
| Price | $10.68 | $6.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 561.9K | 89.5K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.13 |
| EPS | ★ N/A | N/A |
| Revenue | $125,284.00 | ★ $3,569,282.00 |
| Revenue This Year | $12,476.23 | $172.91 |
| Revenue Next Year | $55.17 | $115.71 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 32.89 |
| 52 Week Low | $1.03 | $2.21 |
| 52 Week High | $10.92 | $9.33 |
Technical Indicators
Market Signals| Indicator | AGPU | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 64.17 | 40.93 |
| Support Level | $6.26 | $5.59 |
| Resistance Level | $10.86 | $7.62 |
| Average True Range (ATR) | 1.02 | 0.43 |
| MACD | 0.24 | -0.02 |
| Stochastic Oscillator | 88.39 | 42.11 |
Price Performance
Historical ComparisonAbout AGPU Axe Compute Inc. Common Stock
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).